Quantification of blood dendritic cells in colorectal cancer patients during the course of disease

Pathology and Oncology Research

Volumn 20, Issue 2, 2014, Pages 267-276

  Orsini, Giulia ^a   Legitimo, Annalisa ^a   Failli, Alessandra ^b   Ferrari, Paola ^a   Nicolini, Andrea ^a   Spisni, Roberto ^a   Miccoli, Paolo ^a   Consolini, Rita ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Circulating dendritic cells; Colorectal cancer; Flow cytometry; Immunosuppression

Indexed keywords

ANTIGEN; CD85K ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; LILRB1 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL; CANCER STAGING; CELL COUNT; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MYELOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; TUMOR ESCAPE; VERY ELDERLY; BONE MARROW CELL; CASE CONTROL STUDY; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CASE-CONTROL STUDIES; CELL COUNT; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOID CELLS; RECEPTORS, IMMUNOLOGIC;

EID: 84898833663     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9691-4     Document Type: Article

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Galon J, Fridman WH, Pagès F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67:1883-1886
3. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G (2003) Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 46:33-57
4. Roxburgh CS, McMillan DC (2012) The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 38:451-466
5. Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn C, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ (2004) Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother 53:978-986
6. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn CM, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ (2005) Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 11:2576-2582
7. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C (2007) Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 5:62
8. Schäkel K (2009) Dendritic cells-why can they help and hurt us. Exp Dermatol 18:264-273
9. Mortellaro A, Wong SC, Fric J, Ricciardi-Castagnoli P (2010) The need to identify myeloid dendritic cell progenitors in human blood. Trends Immunol 31:18-23
10. Reizis B (2010) Regulation of plasmacytoid dendritic cell development. Curr Opin Immunol 22:206-211
11. Palucka K, Ueno H, Zurawski G, Fay J, Banchereau J (2010) Building on dendritic cell subsets to improve cancer vaccines. Curr Opin Immunol 22:258-263
12. Fricke I, Gabrilovich DI (2006) Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 35:459-483
13. Lenahan C, Avigan D (2006) Dendritic cell defects in patients with cancer: mechanisms and significance. Breast Cancer Res 8:101
14. Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL, Gonzalez A, Melero I (2007) Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 13:5822-5831
15. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M, Villa ML (2003) Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89:1463-1472
16. Pinzon-Charry A, Maxwell T, López JA (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83:451-461
17. Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M, Lehner F, Manns MP, Korangy F, Greten TF (2006) Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 12:3275-3282
18. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL, Furuya N (2006) Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 55:151-159
19. McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W, Wilson C, Palmer BE, Gonzalez R (2007) Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 14:2854-2860
20. Sciarra A, Lichtner M, Autran GA, Mastroianni C, Rossi R, Mengoni F, Cristini C, Gentilucci A, Vullo V, Di Silverio F (2007) Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate 67:1-7
21. Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Yamao J, Kim S, Terakawa N, Takahashi K, Kwon AH (2012) Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. J Surg Res 173:299-308
22. Ambe K, Mori M, Enjoji M (1989) S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63:496-503
23. Nakayama Y, Inoue Y, Minagawa N, Katsuki T, Nagashima N, Onitsuka K, Tsurudome Y, Sako T, Hirata K, Nagata N, Itoh H (2003) Relationships between S-100 protein-positive cells and clinicopathological factors in patients with colorectal cancer. Anticancer Res 23:4423-4426
24. Inoue Y, Nakayama Y, Minagawa N, Katsuki T, Nagashima N, Matsumoto K, Shibao K, Tsurudome Y, Hirata K, Nagata N, Itoh H (2005) Relationship between interleukin-12-expressing cells and antigen-presenting cells in patients with colorectal cancer. Anticancer Res 25:3541-3546
25. Yuan A, Steigen SE, Goll R, Vonen B, Husbekk A, Cui G, Florholmen J (2008) Dendritic cell infiltration pattern along the colorectal adenoma-carcinoma sequence. APMIS 116:445-456
26. Gulubova MV, Ananiev JR, Vlaykova TI, Yovchev Y, Tsoneva V, Manolova IM (2012) Role of dendritic cells in progression and clinical outcome of colon cancer. Int J Colorectal Dis 27:159-169
27. Huang A, Gilmour JW, Imami N, Amjadi P, Henderson DC, Allen-Mersh TG (2003) Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration. Clin Exp Immunol 134:270-278
28. Bellik L, Gerlini G, Parenti A, Ledda F, Pimpinelli N, Neri B, Pantalone D (2006) Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer. Clin Immunol 121:74-80
29. Schmidt MA, Förtsch C, Schmidt M, Rau TT, Fietkau R, Distel LV (2012) Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment. Radiother Oncol 104:131-138
30. Orsini G, Legitimo A, Failli A, Massei F, Biver P, Consolini R (2012) Enumeration of human peripheral blood dendritic cells throughout the life. Int Immunol 24:347-356
31. Cella M, Döhring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, Colonna M (1997) A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185:1743-1751
32. Vlad G, Chang CC, Colovai AI, Berloco P, Cortesini R, Suciu-Foca N (2009) Immunoglobulin-like transcript 3: A crucial regulator of dendritic cell function. Hum Immunol 70:340-344
33. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, Lipford GB, Zenke M (2004) Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene 331:159-164
34. Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonna M, Adorini L (2005) Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 106:3490-3497
35. Koos D, Josephs SF, Alexandrescu DT, Chan RC, Ramos F, Bogin V, Gammill V, Dasanu CA, De Necochea-Campion R, Riordan NH, Carrier E (2010) Tumor vaccines in 2010: need for integration. Cell Immunol 263:138-147
36. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-277
37. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, Ballestrero A, Brossart P (2008) The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65:191-199
38. Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, Sheahan KD, O'Donoghue DP, Mulcahy HE, Ryan EJ, O'Sullivan JN (2011) Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One 6:e27944
39. Takahashi K, Toyokawa H, Takai S, Satoi S, Yanagimoto H, Terakawa N, Araki H, Kwon AH, Kamiyama Y (2006) Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother 55:775-784
40. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G (2007) Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 178:1534-1541
41. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T, Gires O, Endres S, Hartmann G (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63:6478-6487
42. Pérez-Cabezas B, Naranjo-Gómez M, Fernández MA, Grífols JR, Pujol-Borrell R, Borràs FE (2007) Reduced numbers of plasmacytoid dendritic cells in aged blood donors. Exp Gerontol 42:1033-1038
43. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, Baccarani M, Lemoli RM (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100:230-237
44. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM (2010) Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 72:540-547
45. Hoffmann TK, Müller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ, Whiteside TL (2002) Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8:1787-1793
46. Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N, Kwon AH, Kamiyama Y (2005) Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 114:52-60
47. Wilkinson R, Kassianos AJ, Swindle P, Hart DN, Radford KJ (2006) Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate 66:180-192
48. Suciu-Foca N, Cortesini R (2007) Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 248:59-67
49. Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, Ferrari-Bravo A, Ferrante R, Vigoré L, Rovelli F, Mandalà M, Viviani S, Fumagalli L, Gardani GS (2001) Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 15:140-144
50. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, Grosse-Wilde H, Broelsch CE, Gerken G, Cicinnati VR (2004) Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 10:7260-7269
51. Bennaceur K, Chapman JA, Touraine JL, Portoukalian J (2009) Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim Biophys Acta 1795:16-24
52. Bindea G, Mlecnik B, Fridman WH, Galon J (2011) The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 33:335-340